Riskpilot← Back to searchSign inGet full accessZalVac AB
ABActiveOrg 5592471634Lützengatan 7Manufacture of pharmaceutical preparations · NACE 2120Est. 20201 employees
Revenue 2024
SEK 0
EBITDA margin
—
-332% vs 2023
Equity ratio
79.9%
Financial strength
Net profit 2024
SEK -8,6M
-332% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -8,7M | -332% |
| Net profit | SEK -8,6M | -332% |
| Total assets | SEK 11,9M | +41% |
| Equity | SEK 9,5M | +18% |
| Employees | 1 | — |
Legal name
ZalVac AB
Org number
5592471634
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
10 mars 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget ska bedriva utveckling, produktion och marknadsföring av läkemedel, medicinteknik och in-vitro diagnostik samt därtill hörande konsulttjänster.
Address
Lützengatan 7
Email
ernst.westman@microzeal.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | — | — | −2 004 | −8 657 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 0 | 0 | −2 004 | −8 657 |
| Net financials | — | — | — | 24 | 107 |
| Profit before tax | 0 | 0 | 0 | −1 979 | −8 550 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 0 | 0 | −1 979 | −8 550 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 25 | 25 | 25 | 8 405 | 11 886 |
| Equity | 25 | 25 | 25 | 8 046 | 9 496 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 359 | 2 390 |
| Total debt | — | — | — | 359 | 2 390 |
EBITDA margin
-865700000.0%
This company
15.8%
Market median
-5479114024% vs market
20202024
Equity ratio
79.9%
This company
38.2%
Market median
+109% vs market
20202024
Return on equity
-90.0%
This company
18.4%
Market median
-589% vs market
20202024
Net profit margin
-855000000.0%
This company
8.1%
Market median
-10555555656% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-03-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2020 | |
| Former (4) | ||
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZalVac AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Jan Staffan Normark | Board of Directors | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Per Fredrik Lehmann | Board of Directors | 0 companies |
| Jonathan Jossi Ilicki | Board of Directors | 0 companies |
| Ernst Lennart Westman | Chairman | 0 companies |
| Karl Johan Fredrik Winnerblad | Board of Directors | 0 companies |
| Ingrid Birgitta M Henriques Normark | Deputy Board Member | 0 companies |